Zobrazeno 51 - 60
of 78
pro vyhledávání: '"Rupert Bauersachs"'
Autor:
Stefan J. Cano, Maria Y. Wang, Rupert Bauersachs, Petra M. G. Erkens, Anthonie W. A. Lensing, Luke Bamber, Martin H. Prins
Publikováno v:
Thrombosis Research, 135(2), 281-288. Elsevier Science
Introduction: Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT) and the secondary prevention of recurrent PE and DVT as a fixed-dose, monotherapy regimen that does
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::427f725204c52220c999029b7f14b5c8
https://cris.maastrichtuniversity.nl/en/publications/d2b8b56a-f233-47ce-868b-d8f3e44ff5da
https://cris.maastrichtuniversity.nl/en/publications/d2b8b56a-f233-47ce-868b-d8f3e44ff5da
Autor:
Akos F. Pap, Hervé Decousus, Rupert Bauersachs, Dagmar Kubitza, Anthonie W. A. Lensing, Jan Beyer-Westendorf, Martin H. Prins, Paolo Prandoni
Publikováno v:
Thrombosis Journal
Background: Patients with renal impairment receiving classical anticoagulation for venous thromboembolism (VTE) are at increased risk of bleeding and possibly pulmonary embolism. We examined the efficacy and safety of oral rivaroxaban in patients wit
Publikováno v:
Hämostaseologie. 24:167-172
ZusammenfassungMehrere Studien belegen, dass die subkutane Gabe von niedermolekularem Heparin in der Initialbehandlung der venösen Thrombose mindestens so effektiv und sicher ist wie die intravenöse Gabe von unfraktioniertem Heparin. Damit wird ers
Autor:
Roland Wagner, Edelgard Lindhoff-Last, Rupert Bauersachs, Martina Stein, Britta Wenning, Frank Gerdsen
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 8:347-352
Dispositional risk factors for developing the immune-type of heparin-induced thrombocytopenia (HIT) are yet unclear. This article presents a long-term follow-up of patients with HIT to define possible risk factors that may increase the risk of HIT. T
Autor:
Rupert Bauersachs, Roumen Nakov, Frank Misselwitz, Edelgard Lindhoff-Last, Hans-Klaus Breddin
Publikováno v:
British Journal of Haematology. 118:1137-1142
Summary. The frequency of heparin-induced thrombocytopenia (HIT) varies between different clinical treatment settings and remains unknown for patients treated with unfractionated (UFH) or low-molecular-weight heparin (LMWH) because of deep vein throm
Autor:
Edelgard Lindhoff-Last, Jörn Schmitt, Marek Humpich, Sabine Rödiger, Rupert Bauersachs, Erhard Seifried
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 8:163-167
Lupus anticoagulants (LA) are associated with an increased risk of thrombosis and laboratory detection is of major importance. Multiple tests are available for screening and confirmation, but they differ in sensitivity and specificity, frequently lac
Publikováno v:
British Journal of Haematology. 113:886-890
Only a few patients with heparin-induced antibodies develop heparin-induced thrombocytopenia (HIT). In this study, we investigated whether different immunglobulin classes can be used to differentiate between antibody-positive patients with and withou
Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial
Autor:
Sebastian Schellong, Jan Beyer-Westendorf, Horst E. Gerlach, Eberhard Rabe, Rupert Bauersachs, Katja Jersemann, Kurtulus Sahin
Publikováno v:
Blood. 128:85-85
Background The current standard of therapy in superficial vein thrombosis (SVT) comprises subcutaneous injections of the indirect factorXainhibitorfondaparinuxfor up to 45 days, which was highlyeffectivecompared to placebo in the CALISTO trial. Howev
Autor:
Luke Bamber, Stefan J. Cano, Anthonie W. A. Lensing, Cathleen Ciniglio, Martin H. Prins, Maria Y. Wang, Rupert Bauersachs
Publikováno v:
Thrombosis and Haemostasis, 110(4), 732-741. Georg Thieme Verlag
SummaryRivaroxaban, an oral, direct factor Xa inhibitor, has been approved for the treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE as a fixed-dose, single-drug regimen that does not requi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9774abea719a8907b61263de2e231c5e
https://cris.maastrichtuniversity.nl/en/publications/afcf1419-ad1e-4b9f-b86f-459ae045d2fd
https://cris.maastrichtuniversity.nl/en/publications/afcf1419-ad1e-4b9f-b86f-459ae045d2fd
Autor:
Michael B. Streiff, M Beckers, Manuel Monreal, Mohammed H. Qari, Ajay K. Kakkar, Shaker A. Mousa, Barry M. Brenner, Rupert Bauersachs, Nissim Haim, Paolo Prandoni, Philippe Debourdeau, Anna Falanga, Martin H. Prins, Michel Marty, Alok A. Khorana, C. Baglin, Ingrid Pabinger, Konstantinos N. Syrigos, Dialina Brilhante, Mario Mandalà, Dominique Farge, Henri Bounameaux, Ramón Lecumberri, H. R. Büller, G T Gerotzafias, Simon Noble
Publikováno v:
Journal of Thrombosis and Haemostasis, Vol. 11, No 1 (2013) pp. 56-70
Journal of Thrombosis and Haemostasis, 11(1), 56-70. Wiley
Journal of Thrombosis and Haemostasis, 11(1), 56-70. Wiley
Summary. Background: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide. Objectives: To establish a common international consensus addressin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c2bf2d3717be38b9bf609b87eb0f91d
http://hdl.handle.net/11391/1480953
http://hdl.handle.net/11391/1480953